Abstract
Respiratory syncytial virus (RSV) is a significant cause of mortality and morbidity in infants, elderly, immunocompromised individuals and patients with congenital heart diseases. Despite extensive efforts, a vaccine against RSV is still not available. We have previously reported the development of a subunit vaccine (ΔF/TriAdj) composed by a truncated version of the fusion protein (ΔF) and a polymer-based combination adjuvant (TriAdj). In the present study, we compared inflammatory responses of ΔF/TriAdj-vaccinated and unvaccinated mice following intranasal challenge with RSV. Rapid and early inflammatory responses were observed in lung samples from both groups, but modulated in the vaccinated group seven days after the viral challenge. The underlying mechanism of action of ΔF/TriAdj was further studied through LC-MS-based metabolomic profiling by using 12C- or 13C-dansyl labeling for amine/phenol submetabolome. RSV infection predominantly affected the amino acid biosynthesis pathways and urea cycle, while ΔF/TriAdj modulated the concentrations of almost all of the altered metabolites. Tryptophan metabolites were significantly affected, including indole, L-kynurenine, xanthurenic acid, serotonin, 5-hydroxyindoleacetic acid and 6-hydroxymelatonin. The results from the present study provide further mechanistic insights into the mode of action of this RSV vaccine candidate and have important implications in the design of metabolic therapeutic interventions.
Funding Information
  • Canadian Institutes of Health Research (MOP 42136)
  • Alberta Innovates - Health Solutions
  • Canada Foundation for Innovation
  • Genome Canada
  • Natural Sciences and Engineering Research Council of Canada (90887-2010 RGPIN)
  • Genome Alberta

This publication has 52 references indexed in Scilit: